MiniMed Group Statistics
Total Valuation
MiniMed Group has a market cap or net worth of $6.54 billion. The enterprise value is $6.29 billion.
| Market Cap | 6.54B |
| Enterprise Value | 6.29B |
Important Dates
The last earnings date was Tuesday, September 1, 2026, before market open.
| Earnings Date | Sep 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MiniMed Group has 280.84 million shares outstanding. The number of shares has increased by 4.29% in one year.
| Current Share Class | 280.84M |
| Shares Outstanding | 280.84M |
| Shares Change (YoY) | +4.29% |
| Shares Change (QoQ) | +4.81% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 13.30% |
| Float | 27.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.36 |
| PS Ratio | 2.03 |
| Forward PS | 1.88 |
| PB Ratio | 1.81 |
| P/TBV Ratio | 5.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.95 |
| EV / EBITDA | 22.46 |
| EV / EBIT | 52.02 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 2.14% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $402,750 |
| Profits Per Employee | -$39,250 |
| Employee Count | 8,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MiniMed Group has paid $129.00 million in taxes.
| Income Tax | 129.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 18.19 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 71.17 |
| Average Volume (20 Days) | 1,845,317 |
Short Selling Information
The latest short interest is 5.90 million, so 2.10% of the outstanding shares have been sold short.
| Short Interest | 5.90M |
| Short Previous Month | 6.03M |
| Short % of Shares Out | 2.10% |
| Short % of Float | 21.09% |
| Short Ratio (days to cover) | 5.08 |
Income Statement
In the last 12 months, MiniMed Group had revenue of $3.22 billion and -$314.00 million in losses. Loss per share was -$1.19.
| Revenue | 3.22B |
| Gross Profit | 1.83B |
| Operating Income | 121.00M |
| Pretax Income | -172.00M |
| Net Income | -314.00M |
| EBITDA | 280.25M |
| EBIT | 121.00M |
| Loss Per Share | -$1.19 |
Balance Sheet
The company has $298.00 million in cash and $53.00 million in debt, with a net cash position of $245.00 million or $0.87 per share.
| Cash & Cash Equivalents | 298.00M |
| Total Debt | 53.00M |
| Net Cash | 245.00M |
| Net Cash Per Share | $0.87 |
| Equity (Book Value) | 3.61B |
| Book Value Per Share | 12.86 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was -$197.00 million and capital expenditures -$223.00 million, giving a free cash flow of -$420.00 million.
| Operating Cash Flow | -197.00M |
| Capital Expenditures | -223.00M |
| Depreciation & Amortization | 159.25M |
| Net Borrowing | n/a |
| Free Cash Flow | -420.00M |
| FCF Per Share | -$1.50 |
Margins
Gross margin is 56.67%, with operating and profit margins of 3.76% and -9.75%.
| Gross Margin | 56.67% |
| Operating Margin | 3.76% |
| Pretax Margin | -5.34% |
| Profit Margin | -9.75% |
| EBITDA Margin | 8.70% |
| EBIT Margin | 3.76% |
| FCF Margin | n/a |
Dividends & Yields
MiniMed Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.29% |
| Shareholder Yield | -4.29% |
| Earnings Yield | -4.80% |
| FCF Yield | -6.42% |
Analyst Forecast
The average price target for MiniMed Group is $24.83, which is 6.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.83 |
| Price Target Difference | 6.64% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 9.74% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |